Combining Hypothesis Testing with Bayesian Analyses for Dose Response and Dose Selection
View Presentation *David Gruben, Pfizer Neal Thomas, Pfizer Keywords: Bayesian, Emax, Dose response, Dose selection, Phase 2, Phase 3, Clinical Trial Data from an early study of a binary endpoint was used to inform the design and analysis of a second study. In particular, a Bayesian analysis with priors from the early study will give support to a fitting a 4-parameter Emax model, allowing model convergence when a frequentist approach may only allow for a 3-parameter model. Ease of implementation of the analysis, including discussion of software, will be covered. The actual data from the second study will not yet be available, so simulations may be presented. Definitions of dose and dose-selection criteria will be given and the results of a Bayesian analysis will be contrasted with that of a frequentist analysis.
|
Key Dates
-
April 30 - May 22, 2013
Invited Abstract Submission Open -
June 4, 2013
Online Registration Opens -
August 9 - August 23, 2013
Invited Abstract Editing -
August 23, 2013
Short Course materials due from Instructors -
August 26, 2013
Housing Deadline -
September 9, 2013
Cancellation Deadline and Registration Closes @ 11:59 pm EDT -
September 16 - September 18, 2013
Marriott Wardman Park, Washington, DC